source
- Sanofi to pay $1 billion upfront to expand antibody partnership with RegeneronSanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration. The agreement is timed as the patent protection for Dupixent, the joi…
- BMS flags liver injury cases, including a death, in Phase 3 trial of pulmonary fibrosis drug admilparantBristol Myers Squibb has amended the protocol for its Phase 3 pulmonary fibrosis study of admilparant after reporting several liver injury events, one of which resulted in a patient death. The comp…